Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multi-center, Ib/II Clinical Trial of KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

NCT04601610 is registered in ClinicalTrials.gov with Jiangsu Alphamab Biopharmaceuticals Co., Ltd as lead sponsor.

NCT NCT04601610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04601610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multi-center, Ib/II Clinical Trial of KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma
Lead sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase
Phase 1/2
Overall status
Terminated
Start date
June 7, 2021
Completion date
May 30, 2022
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hcc